Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
Ruxolitinib is a Janus kinase inhibitor that is used in the treatment of intermediate or high risk myelofibrosis and resistant forms of polycythemia vera and graft-vs-host disease. Ruxolitinib is associated with transient and usually mild elevations in serum aminotransferase during therapy and to rare instances of self-limited, clinically apparent idiosyncratic acute liver injury and to cases of reactivation of hepatitis B in susceptible individuals.
Ruxolitinib cas 941678-49-5; INCB018424; Ruxolitinib (INCB018424); (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile; INCB-018424; INCB 018424; UNII-82S8X8XX8H;
Ruxolitinib API Cas 941678-49-5,INCB018424 Ruxolitinib Offering,Jakafi Roxolitinib Offering.
Ruxolitinib cas 941678-49-5; INCB018424; Ruxolitinib (INCB018424); (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile; INCB-018424; INCB 018424; UNII-82S8X8XX8H; Â Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com
In recent days, Shaanxi Province held a working conference to revitalize the equipment manufacturing industry and proposed that during the “Eleventh Five-Year Plan†period, one of the eight areas in which Shaanxi's equipment manufacturing industry seeks to break through is to focus on the development of heavy-duty trucks and chassis of more than 15 tons. , high-end buses and urban low-floor buses, economical cars and electric hybrid cars. Shaanxi Automobile Group, as a leading enterprise in the automotive manufacturing industry in Shaanxi Province, had its output value exceeded 8 billion yuan in the first 11 months of this year. Sales growth ranked first in the industry for 11 consecutive months.
At present, Shaanxi Automobile Group has a market share of more than 95% in the 5-ton military vehicle market. The heavy-duty card market with more than 15 tons continues to maintain its leading position. The market share of 25 tons or above is 70%. Shaanxi Automobile Group has successfully completed the target of 30,000 heavy-duty vehicle production and sales this year.
It is reported that Shaanxi Automobile Group will focus on heavy trucks to fully develop all types of commercial vehicles, drive the development of key assemblies and general parts and components, and gradually realize internationalization, develop automotive derivative industries, and form more than 200,000 vehicles, with an output value exceeding 500. The over 100 million yuan of large-scale enterprise groups have entered the top 15 in the Chinese auto industry and built up a pillar industry for Shaanxi's economic development.
View related topics: Shaanxi Auto's second-generation triple card debut